Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3158140 | 1.00 | MAPT (0.53) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL16745722 | 0.90 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL31405642 | 0.90 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL6308419 | 0.90 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL28467960 | 0.88 | MAPT (0.53) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL28467961 | 0.88 | MAPT (0.53) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL16745723 | 0.86 | ALDH1A1 (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL5841482 | 0.85 | MAPT (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4952874 | 0.84 | MAPT (0.53) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL8988205 | 0.84 | MAPT (0.53) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4405638-A | ANTITUSSIVE AGENTS; ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A (IT) | 1983-09-20 | — | — | US | claimed |
| EP-0497525-B2 | Pneumococcal polysaccharide conjugate vaccine | MERCK & CO INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20050271608-A1 | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives | GUPTA SHYAM K | 2005-12-08 | — | — | US | disclosed |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-0497525-B1 | Pneumococcal polysaccharide conjugate vaccine | MERCK & CO INC (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5623057-A | IMMUNOGENIC PROTEIN COVALENTLY LINKED TO POLYSACCHARIDE DERIVED FROM STREPTOCOCCUS PNEUMONIAE | MERCK & CO., INC. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0497525-A2 | Pneumococcal polysaccharide conjugate vaccine | MERCK & CO. INC. (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0467714-A1 | The class II protein of the outer membrane of neisseria meningitidis | MERCK & CO. INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| EP-0161188-B1 | COVALENTLY-MODIFIED BACTERIAL POLYSACCHARIDES, STABLE COVALENT CONJUGATES OF SUCH POLYSACCHARIDES AND IMMUNOGENIC PROTEINS WITH BIGENERIC SPACERS, AND METHODS OF PREPARING SUCH POLYSACCHARIDES AND CONJUGATES AND OF CONFIRMING COVALENCY | MERCK & CO. INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4882317-A | SOLUBILIZATION | MERCK & CO., INC. (US) | 1989-11-21 | — | — | US | disclosed |
| US-4695624-A | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | MERCK & CO., INC. (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0161188-A2 | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | MERCK & CO. INC. (US) | 1985-11-13 | — | — | EP | disclosed |
| US-4405638-A | ANTITUSSIVE AGENTS; ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A (IT) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | MAPT 3740/4885KDM4E 1902/4885THRB 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.